Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Metabolic Syndrome Observation on a Regional Basis (ORSA Umbria)

This study has been completed.
Sponsor:
Information provided by:
AstraZeneca
ClinicalTrials.gov Identifier:
NCT00933010
First received: July 2, 2009
Last updated: October 12, 2010
Last verified: October 2010

July 2, 2009
October 12, 2010
October 2009
October 2010   (final data collection date for primary outcome measure)
  • Prevalence of Metabolic Syndrome in Primary Care Population [ Time Frame: July 2009 - March 2010 ] [ Designated as safety issue: No ]
  • Concomitant presence of other CV risk factors [ Time Frame: July 2009 - March 2010 ] [ Designated as safety issue: No ]
Same as current
Complete list of historical versions of study NCT00933010 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Metabolic Syndrome Observation on a Regional Basis
Osservatorio Regionale Sulla Sindrome metabolicA

The aim of the study is to assess the prevalence of Metabolic Syndrome in Italy on a regional basis, defined according to NCEP/ATPIII Guidelines criteria.

Not Provided
Observational
Observational Model: Ecologic or Community
Time Perspective: Cross-Sectional
Not Provided
Not Provided
Non-Probability Sample

Primary care clinic

Metabolic Syndrome
Not Provided
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
1600
October 2010
October 2010   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Patient aged between 18 and 75 years
  • Signed Informed consent
  • Laboratory analysis (lipidic profile and glycemia) performed in the last year

Exclusion Criteria:

  • Pregnancy or breast feeding
  • Patients enrolled in clinical studies which the aim is to evaluate the efficacy and/or tolerability of anti-hypertensive and/or lipid lowering drugs
  • Subjects with serious or unstable medical or psychological conditions that, in the opinion of the investigator, would compromise the subject's successful participation in the study
Both
18 Years to 75 Years
No
Contact information is only displayed when the study is recruiting subjects
Italy
 
NCT00933010
NIS-CIT-DUM-2008/1
No
MC MD, AstraZeneca
AstraZeneca
Not Provided
Study Chair: Mario Mangrella AstraZeneca S.p.A., R&D
Study Director: Raffaele Sabia AstraZeneca S.p.A., R&D
AstraZeneca
October 2010

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP